SenderraRx, an independent specialty pharmacy, announced on Thursday that it has earned reaccreditation in Specialty Pharmacy from the Accreditation Commission for Health Care (ACHC), including a Distinction in Oncology.
The Oncology Distinction recognises Senderra's oncology-focused clinical oversight, medication management, patient education, adherence support, and care coordination for patients navigating complex cancer therapies.
The ACHC reaccreditation adds to Senderra's existing URAC accreditations in Specialty Pharmacy and Mail Service Pharmacy under URAC's version 6.0 standards. Collectively, these accreditations show that Senderra's pharmacy operations, medication distribution, patient management, and service practices have been independently evaluated against current industry standards.
Medtronic confirms separation of MiniMed
SenderraRx receives reaccreditation in Specialty Pharmacy from ACHC
EMA issues positive CHMP opinion for Revolution Medicines' RASONQUE in metastatic pancreatic cancer
Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe
SciBase technology selected as primary endpoint in NIH-led skin exposure study
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Solvonis signs Portugal agreement to assess European expansion of Phase 3 alcohol addiction trial
Foresee gains NMPA approval for CAMCEVI 42 mg in China
ABL Texcell Diagnostics acquires IntegraGen assets to expand into precision oncology